8 terminated. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
Follow Pituitary Neoplasms: new trials by email Literature Review of Pituitary Neoplasms trials Research Report on Pituitary Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Capecitabine, Temozolomide - Recurrent Pituitary Adenomas | Phase 2 | Terminated | Weill Medical College of Cornell University | 1 | 2019-05-21 | 2022-08-09 |
| Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Pasireotide LAR - Pituitary Tumor, ACTH-producing Pituitary Tumour | Phase 2 | Terminated | Columbia University | 4 | 2017-07-10 | 2021-04-27 |
| Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Photofrin photodynamic therapy. - Brain Tumor, Recurrent | Phase 2 | Terminated | Harry T Whelan, MD | 1 | 2015-06-01 | 2019-08-20 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| Pasireotide Therapy in Patients With Nelson's Syndrome Pasireotide - Nelson Syndrome | Phase 2 | Terminated | Sheffield Teaching Hospitals NHS Foundation Trust | 8 | 2011-03-01 | 2016-11-02 |
| Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin pasireotide LAR - Pancreatic Neoplasm, Pituitary Neoplasm | Phase 2 | Terminated | Novartis Pharmaceuticals | 118 | 2009-09-01 | 2016-07-26 |
| Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas pasireotide LAR - Gonadotroph Adenomas | Phase 2 | Terminated | University of Pennsylvania | 2 | 2009-06-01 | 2017-11-28 |
| Rosiglitazone in Treating Patients With Pituitary Tumors rosiglitazone maleate - Brain and Central Nervous System Tumors | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 1 | 2006-10-01 | 2020-08-14 |
Nelson Syndrome (2) · ACTH Syndrome, Ectopic (1) · Adrenocortical Hyperfunction (1) · Astrocytoma (1) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Chordoma (1) · Craniopharyngioma (1) · Germinoma (1) · Glioblastoma (1) · Glioma (1) · Meningioma (1) · Neoplasms, Germ Cell and Embryonal (1) · Neuroectodermal Tumors, Primitive (1)
Brain Diseases (8) · Central Nervous System Diseases (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Hypothalamic Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Nervous System Diseases (8) · Pituitary Diseases (8) · Hypothalamic Neoplasms (7) · Nervous System Neoplasms (7) · Supratentorial Neoplasms (7) · Brain Neoplasms (6) · Central Nervous System Neoplasms (6) · ACTH-Secreting Pituitary Adenoma (2)
pasireotide (4) · Cabergoline (1) · Capecitabine (1) · Rosiglitazone (1) · Temozolomide (1)
Novartis Pharmaceuticals (2) · Columbia University (1) · Harry T Whelan, MD (1) · Jonsson Comprehensive Cancer Center (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · University of Pennsylvania (1) · Weill Medical College of Cornell University (1)
United States (7) · Argentina (2) · Brazil (2) · France (2) · Germany (2) · Italy (2) · Mexico (2) · Spain (2) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Greece (1) · Hungary (1) · India (1)
Anthony Heaney, MD (1) · Harry T Whelan, MD (1) · John Newell-Price (1) · Pamela Freda, MD (1) · Peter J. Snyder, MD (1) · Rajiv Magge, MD (1)
2008 (1), 2009 (1)